Lonza Group stock keeps 2026 targets intact after Q3 update

Lonza Group stock traded at 706.90 euros on Lang & Schwarz at 9:38 a.m. CET on Monday, November 2, 2026. A verified Xetra closing comparison was not available for the quote, so the market indication ends with the current price.

Investors are weighing Lonza's unchanged 2026 outlook after the Swiss contract development and manufacturing organization said its third-quarter performance was in line with expectations. In its October 14 announcement, Lonza said all business platforms performed in line with expectations.

2026 targets remain unchanged

Lonza continues to forecast constant-currency sales growth of 11% to 12% for 2026 and a CORE EBITDA margin of 33% to 34%. The company also expects foreign-exchange effects to reduce reported sales growth by 2% to 3% this year. Capsules & Health Ingredients is expected to deliver mid-single-digit constant-currency sales growth and further CORE EBITDA margin expansion for the full year.

The outlook follows an upgrade after the first half of 2026 rather than a fresh reduction or increase in the current-year targets. That distinction matters for investors because the latest third-quarter update supports continuity in the forecast while leaving execution and currency effects as the main variables for the reported result.

Higher ambition beyond 2026

Lonza has raised its medium-term organic growth model to 10% to 13% at constant exchange rates on average over time. It now aims for a CORE EBITDA margin in the high thirties over the medium term, with CORE EBITDA expected to grow faster than sales.

Management links the profitability ambition to maturing high-return growth projects, better operational and commercial execution, capital-spending performance and continued overhead discipline. The company also added a medium-term return-on-invested-capital ambition of two to three times its current weighted average cost of capital and expects free-cash-flow conversion to improve over time.

The strategic framework reflects Lonza's shift toward a focused CDMO group after the exit from the Capsules & Health Ingredients business. Lonza said the transaction involving a 60% stake agreed with Lone Star Funds is expected to close before the end of 2026.

The real-time quote of Lonza Group stock remains the direct market reference for the latest trading indication.

Broader European equities remain sensitive to changes in growth expectations, interest rates and currency markets; current market reports are available through Current market reports.

More news and analyses on Lonza Group stock cover the company's strategy, outlook and investor events.